Advertisement
Advertisement

HIV Care Today


HIV Epidemiology and Something Even Many Smart Medical Students Don't Know
By Paul E. Sax, M.D.
June 4, 2011

Periodically I like to give an informal quiz to the medical students about HIV epidemiology. It's a multiple choice question that goes something like this:

Read more …


Surprise! It's Generic Combivir!
By Paul E. Sax, M.D.
May 26, 2011

FDA granted approval for a generic formulation fixed dose combination of lamivudine and zidovudine tablets, 150 mg/300 mg, two nucleoside analogue reverse transcriptase inhibitors, indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection ... FDA has determined that the generic formulation is bioequivalent and, therefore, therapeutically equivalent to the reference listed drug, Combivir Tablets...

Read more …


Rilpivirine Approved -- the "iPod" of NNRTIs?
By Paul E. Sax, M.D.
May 23, 2011

FDA approved Edurant (rilpivirine) 25 mg tablets, a new non-nucleoside reverse transcriptase inhibitor (NNRTI) for the treatment of HIV. Rilpivirine is an antiviral drug that helps to block reverse transcriptase, an enzyme necessary for HIV replication. The recommended dose of rilpivirine is one 25 mg tablet once daily taken orally with a meal.

Read more …


HIV Exceptionalism and the Department of Unintended Consequences
By Paul E. Sax, M.D.
May 18, 2011

Maybe I'm being presumptuous here, but one of these -- virologic suppression -- completely blows the rest of them away. Sure, the others are worthwhile, but data linking them to improved outcomes for people with HIV are either pretty weak (adherence counseling, flu vaccine) or nonexistent (toxoplasmosis serology).

Read more …


HPTN 052 Results -- Another Win for Early HIV Therapy
By Paul E. Sax, M.D.
May 12, 2011

The results of the HPTN Study 052 -- which randomized 1,763 serodiscordant couples to early vs delayed ART to evaluate whether this reduced the risk of HIV transmission -- have just been released:

Read more …


Is There a Future for HIV-Infected Patients in "Deep Salvage"?
By Nelson Vergel, B.S.Ch.E., M.B.A.
May 3, 2011

"Deep salvage patients no longer exist. The ones in that situation are already dead or have responded to the latest HIV antiretrovirals."

Read more …


A "New" Antiretroviral Option Quietly Enters the Market
By Paul E. Sax, M.D.
April 25, 2011

There's a new antiretroviral option out there, a 400-mg extended-release tablet formulation of nevirapine that can be dosed once daily.

Read more …


Organ Transplants From HIV-Infected Donors
By Paul E. Sax, M.D.
April 18, 2011

On the heels of last month's report of HIV transmission from an organ donor -- covered here in Journal Watch -- comes this remarkable article in The New York Times about lifting the ban on organ donation from donors known to be HIV positive.

Read more …


Where Are the Clinical Trials That Focus on HIV-Affected Women?
By Bethsheba Johnson, G.N.P.-B.C., A.A.H.I.V.S.
April 12, 2011

As I look back over the recent past in HIV research, I am impressed at what advancements we have made, yet disturbed at what little we know and have done regarding HIV prevention and treatment in women.

Read more …


Journal Club: Even When You Think You Should Wait, It's Probably Time to Start
By Paul E. Sax, M.D.
April 8, 2011

Both apply to certain patients in whom we might consider waiting to start treatment -- but both these studies suggest we do otherwise.

Read more …

 < Prev  |  1  |  …  |  10  |  11  |  12  |  13  |  Next > 

Get email notifications every time HIV Care Today is updated.



This article was provided by TheBodyPRO.com.
 

Advertisement